Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals

[1]  F. Vizoso,et al.  Prognostic significance of inflammatory factors expression by stroma from breast carcinomas. , 2016, Carcinogenesis.

[2]  Wassim Raffoul,et al.  A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response. , 2016, Cancer cell.

[3]  A. Zannettino,et al.  Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche , 2015, Nature Communications.

[4]  Brendan M Leung,et al.  Modeling Selective Elimination of Quiescent Cancer Cells from Bone Marrow , 2015, Neoplasia.

[5]  D. El-Ashry,et al.  Hierarchical paracrine interaction of breast cancer associated fibroblasts with cancer cells via hMAPK-microRNAs to drive ER-negative breast cancer phenotype , 2015, Cancer biology & therapy.

[6]  A. Mastro,et al.  Dormancy and growth of metastatic breast cancer cells in a bone-like microenvironment , 2015, Clinical & Experimental Metastasis.

[7]  Stephen T. C. Wong,et al.  The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. , 2015, Cancer cell.

[8]  P. Heikkilä,et al.  Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells , 2014, Breast Cancer Research.

[9]  W. Carter,et al.  CDCP1 Identifies a CD146 Negative Subset of Marrow Fibroblasts Involved with Cytokine Production , 2014, PloS one.

[10]  P. Nelson,et al.  Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways , 2014, Oncotarget.

[11]  N. Kosaka,et al.  Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells , 2014, Science Signaling.

[12]  Michael L. Wang,et al.  Osteoblastic niche supports the growth of quiescent multiple myeloma cells. , 2014, Blood.

[13]  R. Sandstrom,et al.  Functionally and phenotypically distinct subpopulations of marrow stromal cells are fibroblast in origin and induce different fates in peripheral blood monocytes. , 2014, Stem cells and development.

[14]  D. Hawke,et al.  Molecular characterization of exosome-like vesicles from breast cancer cells , 2014, BMC Cancer.

[15]  Yong Song Gho,et al.  Importance of exosome depletion protocols to eliminate functional and RNA-containing extracellular vesicles from fetal bovine serum , 2014, Journal of extracellular vesicles.

[16]  J. Slingerland,et al.  Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy , 2013, Nature Reviews Cancer.

[17]  A. Tutt,et al.  A novel model of dormancy for bone metastatic breast cancer cells. , 2013, Cancer research.

[18]  R. Bernards,et al.  A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences , 2013, Molecular oncology.

[19]  J. Foekens,et al.  Selection of Bone Metastasis Seeds by Mesenchymal Signals in the Primary Tumor Stroma , 2013, Cell.

[20]  David J Beebe,et al.  Hormonally responsive breast cancer cells in a microfluidic co-culture model as a sensor of microenvironmental activity. , 2013, Integrative biology : quantitative biosciences from nano to macro.

[21]  X. Zhang,et al.  BMP/Coco antagonism as a deterministic factor of metastasis dormancy in lung , 2013, Breast Cancer Research.

[22]  P. V. van Diest,et al.  Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases , 2012, Cancer.

[23]  A. Brivanlou,et al.  The BMP Inhibitor Coco Reactivates Breast Cancer Cells at Lung Metastatic Sites , 2012, Cell.

[24]  C. Klinge.  miRNAs and estrogen action , 2012, Trends in Endocrinology & Metabolism.

[25]  L. Murphy,et al.  Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer. , 2012, Endocrine-related cancer.

[26]  M. Watabe,et al.  Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone , 2011, The Journal of experimental medicine.

[27]  L. Donehower,et al.  P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis , 2011, Breast Cancer Research and Treatment.

[28]  P. Bragado,et al.  ERK1/2 and p38α/β Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease , 2011, Clinical Cancer Research.

[29]  Chenguang Wang,et al.  Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer , 2011, Nature Medicine.

[30]  K. Pienta,et al.  Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. , 2011, The Journal of clinical investigation.

[31]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[32]  Pieter Wesseling,et al.  Receptor conversion in distant breast cancer metastases , 2010, Breast Cancer Research.

[33]  M. Lacey,et al.  Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence , 2010, Breast Cancer Research and Treatment.

[34]  C. Dinarello.  Why not treat human cancer with interleukin-1 blockade? , 2010, Cancer and Metastasis Reviews.

[35]  K. Horwitz,et al.  Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer. , 2010, Cancer research.

[36]  P. Triozzi,et al.  Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanoma. , 2010, Anticancer research.

[37]  T. Spelsberg,et al.  Development and characterization of a conditionally immortalized human fetal osteoblastic cell line , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[38]  H. Doihara,et al.  Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation. , 2008, The Journal of endocrinology.

[39]  T. Fehm,et al.  ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients , 2008, Breast Cancer Research.

[40]  A. Giordano,et al.  Epigenetic modulation of estrogen receptor-alpha by pRb family proteins: a novel mechanism in breast cancer. , 2007, Cancer research.

[41]  H. Alexander,et al.  Journal of Translational Medicine Interleukin-1 and Cancer Progression: the Emerging Role of Interleukin-1 Receptor Antagonist as a Novel Therapeutic Agent in Cancer Treatment , 2022 .

[42]  Y. Sugimoto,et al.  Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. , 2006, Anticancer research.

[43]  J. Cowland,et al.  IL-1β-Specific Up-Regulation of Neutrophil Gelatinase-Associated Lipocalin Is Controlled by IκB-ζ1 , 2006, Journal of Immunology.

[44]  Michael C. Ostrowski,et al.  ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis , 2005, Oncogene.

[45]  S. Kurtzman,et al.  The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. , 2003, International journal of oncology.

[46]  J. Aguirre-Ghiso,et al.  ERKMAPK Activity as a Determinant of Tumor Growth and Dormancy; Regulation by p38SAPK , 2003 .

[47]  Kenneth P Nephew,et al.  The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells. , 2003, Molecular endocrinology.

[48]  Y. Iwakura,et al.  IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[49]  P. Dennis,et al.  Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. , 2002, Molecular cancer therapeutics.

[50]  V. Keshamouni,et al.  Mechanism of 17-β-Estradiol-induced Erk1/2 Activation in Breast Cancer Cells , 2002, The Journal of Biological Chemistry.

[51]  M. Martin,et al.  Regulation of estrogen receptor-alpha gene expression by epidermal growth factor. , 2000, The Journal of endocrinology.

[52]  M. Martin,et al.  Role of insulin‐like growth factor‐I in regulating estrogen receptor‐α gene expression , 2000 .

[53]  B. O’Malley,et al.  Proteasome-dependent degradation of the human estrogen receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[54]  D. Fan,et al.  Antitumor effects of liposomal IL1α and TNFα against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice , 1995, Clinical & Experimental Metastasis.

[55]  B. Torok-Storb,et al.  Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. , 1995, Blood.

[56]  M. Sgagias,et al.  Interleukin-1α and Interleukin-6 Act Additively to Inhibit Growth of MCF-7 Breast Cancer Cells in Vitro , 1993 .

[57]  M. Sgagias,et al.  Interleukin-1α and Tumor Necrosis Factor-α (TNFα) Inhibit Growth and Induce TNF Messenger RNA in MCF-7 Human Breast Cancer Cells , 1991 .

[58]  M. Sgagias,et al.  Interleukin 1α Blocks Estradiol-stimulated Growth and Down-regulates the Estrogen Receptor in MCF-7 Breast Cancer Cells in Vitro , 1991 .

[59]  J. Huang,et al.  In vivo inhibition of tumor growth of B16 melanoma by recombinant interleukin 1 beta. I. Tumor inhibition parallels lymphocyte-activating factor activity of interleukin 1 beta proteins. , 1990, Cytokine.

[60]  B. Woda,et al.  Radiosensitivity of permanent human bone marrow stromal cell lines: effect of dose rate. , 1988, International journal of radiation oncology, biology, physics.

[61]  L. Tamarkin,et al.  Interleukin-1 directly regulates hormone-dependent human breast cancer cell proliferation in vitro. , 1988, Molecular endocrinology.

[62]  M. Yamada,et al.  Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors. , 1986, Japanese journal of cancer research : Gann.

[63]  A. Tabilio,et al.  Haematopoietic and stromal stem cell regulation by extracellular matrix components and growth factors. , 2009, Journal of stem cells.

[64]  Archana Dhasarathy,et al.  The Transcription Factor Snail Mediates Epithelial to Mesenchymal Transitions by Repression of Estrogen Receptor - , 2007 .

[65]  J. Cowland,et al.  IL-1beta-specific up-regulation of neutrophil gelatinase-associated lipocalin is controlled by IkappaB-zeta. , 2006, Journal of immunology.

[66]  H. Stevenson,et al.  Molecular and cellular determinants of estrogen receptor alpha expression. , 2004, Molecular and cellular biology.

[67]  J. Aguirre-Ghiso,et al.  ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). , 2003, Cancer research.

[68]  R. Brueggemeier,et al.  Increased proteasome‐dependent degradation of estrogen receptor‐alpha by TGF‐β1 in breast cancer cell lines , 2003, Journal of cellular biochemistry.